WO2014154179A1 - 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 - Google Patents
2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 Download PDFInfo
- Publication number
- WO2014154179A1 WO2014154179A1 PCT/CN2014/074318 CN2014074318W WO2014154179A1 WO 2014154179 A1 WO2014154179 A1 WO 2014154179A1 CN 2014074318 W CN2014074318 W CN 2014074318W WO 2014154179 A1 WO2014154179 A1 WO 2014154179A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- reaction
- androst
- added
- water
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 148
- 238000000034 method Methods 0.000 claims abstract description 16
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 12
- 208000005400 Synovial Cyst Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000004090 neuroprotective agent Substances 0.000 claims description 6
- 230000000324 neuroprotective effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- LYFPAZBMEUSVNA-FZFXZXLVSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 LYFPAZBMEUSVNA-FZFXZXLVSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 229940126214 compound 3 Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 71
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 38
- 239000000243 solution Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 28
- 239000012065 filter cake Substances 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 230000007935 neutral effect Effects 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 238000000967 suction filtration Methods 0.000 description 18
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000008187 granular material Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000002490 cerebral effect Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 12
- 238000010992 reflux Methods 0.000 description 11
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 210000001328 optic nerve Anatomy 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000016273 neuron death Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000019025 Hypokalemia Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- OXKUGIFNIUUKAW-UHFFFAOYSA-N n,n-dimethylformamide;hydrazine Chemical compound NN.CN(C)C=O OXKUGIFNIUUKAW-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000024896 potassium deficiency disease Diseases 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003810 Jones reagent Substances 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- -1 choline ester Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 208000032253 retinal ischemia Diseases 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Definitions
- the present invention relates to a polyhydroxyfluorenone, specifically 2?, 3?, 5?-trihydroxy-androst-6-one, and a process for its preparation and medical use. Background technique
- Polyhydroxy fluorenone is an important class of compounds widely found in nature. Many of the hydroxy ketones extracted from marine organisms and terrestrial plants have important physiological functions such as anti-tumor and immune enhancement, for example, ecdysterone and canola sterol. The compounds have a function of promoting plant growth.
- the present invention provides a novel polyhydroxy fluorenone substance, namely 2 ⁇ , 3 ⁇ , 5 ⁇ -trihydroxy-androst--0-one (hereinafter sometimes referred to as "YC-1 0", “compound (1)”, “compound” ⁇ , and is used interchangeably in this article), its structural formula is as follows (I)
- the compound of the formula (I) is not naturally occurring, but is obtained by the inventors of the present application by a synthetic method.
- the polyhydroxyfluorenone has a relatively simple structure relative to a naturally occurring polyhydroxy fluorenone. For example, it does not have long or complex side chains, thus facilitating artificial synthesis.
- drug delivery is facilitated by a reduction in molecular weight and simplification of the spatial stereostructure.
- the disappearance of the side chains also reduces the possibility of interaction with other substances.
- the 1st-position of the compound (I) does not have a side chain, which may increase the bioavailability of the compound in vivo and eliminate its hormone-like action.
- the unique stereo configuration has the potential to increase its stereoselectivity and have better biological activity.
- the compounds of formula (I) have been shown to still have specific pharmacological effects and have potential pharmaceutical uses.
- tests have confirmed the use of the compound for anti-tumor use and for protecting nerve cells, especially optic ganglion cells.
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), and a pharmaceutically acceptable carrier.
- “Therapeutically effective amount” means that the amount of the compound when administered to an individual for treating a disease is sufficient to effect treatment of the disease.
- the “therapeutically effective amount” may vary depending on the compound, the disease and its severity, the age, weight, etc. of the individual being treated.
- “Pharmaceutically acceptable carrier” means a diluent, adjuvant, excipient, or the like which can be administered with a compound of the present invention.
- Another aspect of the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), and a second neuroprotective agent.
- the second neuroprotective agent is different from the compound of the present invention and can be used in combination with the compound of the present invention for achieving neuronal cell protection.
- the second neuroprotective agent is an optic ganglion cell protectant.
- a further aspect of the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), and a second anti-tumor drug.
- the second neuroprotective agent differs from the compounds of the invention and can be used in combination with the compounds of the invention for achieving anti-tumor applications.
- tumor refers to the malignant or benign growth of cells in the skin or body organs, such as, but not limited to, the breast, the prostate, the lungs, the kidneys, the pancreas, the stomach or the intestines. Malignant tumors invade adjacent tissues and spread (metastasize) to distant organs such as bone, liver, lung or brain.
- tumor as used herein includes metastatic tumor cell types such as, but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma, as well as tissue cancer types such as, but not limited to, colorectal cancer, prostate cancer, Small cell lung cancer and non-small cell lung cancer, ? L cancer, pancreatic cancer, bladder cancer, kidney cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, prostate cancer, and uterine smooth hunger sarcoma.
- metastatic tumor cell types such as, but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma
- tissue cancer types such as, but not limited to, colorectal cancer, prostate cancer, Small cell lung cancer and non-small cell lung cancer, ? L cancer, pancreatic cancer, bladder cancer, kidney cancer, gastric cancer,
- a further aspect of the invention provides the use of a compound of formula (I) for the preparation of a neuroprotective or antitumor drug.
- the compound of the formula (I) of the present invention has been experimentally confirmed to have an effect of inhibiting the growth of tumor cells, and the tumor inhibition rate is dose-dependent, and it also has a significant neuroprotective effect.
- a further aspect of the invention provides a method of treating or ameliorating a disease or condition, such as a retinal nerve injury caused by a plurality of disease factors or a neurological damage associated with the central nervous system, such as retinal ischemia, trauma, and acute and Optic nerve damage caused by chronic cyanescence, hypertension and diabetes leading to hypertensive retinopathy and diabetic retinal damage, retinitis pigmentosa and macular degeneration, or stroke, brain injury, spinal injury, Parkinson's disease (Parkinson ' Central nervous system diseases such as s disease, PD), Alzheimer's disease (AD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS).
- the method comprises administering to a subject a therapeutically effective amount of a compound of formula (I), or a prodrug, solvate thereof, or a pharmaceutical composition provided herein, provided herein.
- prodrug means a compound having a cleavable group and which becomes a pharmaceutically active compound of the formula (I) in vivo by hydrolysis or under physiological conditions, including a derivative of the compound of the present invention.
- examples of such include, but are not limited to, choline ester derivatives and the like, N-alkyl morpholine esters, and the like.
- Solvate means a form of a compound which is usually associated with a solvent by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid, and the like.
- the compounds of the invention may be prepared, for example, in crystalline form and may be solvated or hydrated.
- Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and also include chemical solvates and non-stoichiometric solvates. In some cases, the solvate can be separated, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid.
- solvent includes a solution phase and a separable solvate. Representative solvates include hydrates, ethanolates, and methanolates.
- a process for the preparation of the above compound of the formula (I) of the present invention which is prepared by reacting androst-5-het-3-ol as a raw material, ie, 3 (3-p-toluene). Sulfonyloxy-5a-hydroxy-androst-6-one, which is subjected to elimination to give compound IX, ie 5a-hydroxy-androst-2-ene-0-one, which is then oxidized and hydrolyzed via a 2-position double bond. The reaction gave Compound I.
- the compound VI can be produced in various ways, for example:
- Compound VI is prepared by using male-5-h--3-ol as a raw material, oxidizing, alkaline hydrolysis, NBS oxidation and p-toluenesulfonyl chloride protection by H 2 ⁇ 2 /carboxylic acid system.
- the method comprises the following steps: ( la) adding the compound androst-5-en-3-ol and formic acid in a reaction flask, adding hydrogen peroxide at a low temperature, reacting for 1 to 2 hours, heating, adding water, stirring and dispersing, and pumping Filtration, drying to give a white solid compound II, the compound male guan-5-5--3-ol: formic acid: hydrogen peroxide: 1: 1 0 ⁇ 30: 0.5 ⁇ 3 (w: v: v); ( lb) in the reaction flask Add alkaline methanol solution, add compound II in proportion, force Heat reflux for ⁇ 2h, the reaction solution is poured into water, dispersed, filtered and dried to obtain white solid compound III.
- the alkaline methanol solution is: any one of potassium hydroxide, sodium hydroxide and sodium methoxide in methanol.
- the alkali concentration of the reaction solution is: 2 ⁇ 1 0%; ( lc)
- compound III and an appropriate amount of dioxane and water are added, NBS is added in portions, and after reacting for 2 to 4 hours, sodium sulfite is added and filtered.
- Compound VI was prepared by using male-reactive 5-5--3-ol as a raw material, by oxidation of m-chloroperoxybenzoic acid, acid hydrolysis, NBS oxidation and p-toluenesulfonyl chloride.
- the method comprises: (2 ⁇ ) adding a compound androst-5-en-3-ol to a reaction flask and
- the acid in the acidic solution of acetone is: sulfuric acid and periodic acid
- compound IV acetone: the acid of IN is 1: 20 ⁇ 30: 5 ⁇ 1 0 (w : v : v)
- (2c) In the reaction flask, add compound III and appropriate amount of dioxane and water, add NBS in batches, react for 2 ⁇ 4h, add sodium sulfite, filter cake, wash and wash until Neutral, dry white solid compound V; (2d) In the reaction flask, add appropriate amount of pyridine, compound V and p-toluenesulfonyl chloride, stir at room temperature for 24 ⁇ 36h, add to iced aqueous hydrochloric acid, filter cake, wash and wash Neutral, dry white solid compound VI.
- Compound VI is prepared by using male-5-en-3-ol as a raw material, by p-toluenesulfonyl chloride protection, oxidation of m-chloroperoxybenzoic acid, and oxidation of Jones reagent.
- the method comprises the following steps: (3a) adding a compound, androst-5-en-3-ol, anhydrous pyridine and p-toluenesulfonyl chloride in a reaction flask, stirring at room temperature, and pouring into an aqueous solution of glacial hydrochloric acid after completion of the reaction. In the middle, stirring, suction filtration, the filter cake is washed with water to neutral, and dried to give a white solid compound VII; (3b) Compound VII and dichloromethane are added to the reaction flask, and m-chloroperoxybenzoic acid is added in portions with stirring, ice.
- the compound IX is obtained, for example, by the following steps: adding an appropriate amount of the compound VI, DMF, ⁇ 3 and LiBr to the reaction flask, heating under reflux, and pouring the reaction solution into an aqueous solution of glacial hydrochloric acid, and stirring. After suction filtration, the filter cake was washed until neutral and dried to give a white solid compound IX.
- compound VI: DMF is 1:3 to 15 (w: V);
- compound VI: Li 2 C ⁇ 3 : LiBr is: 1 : 4-12 : 4 to 12 (M: M: M).
- the compound I can be produced by the same method from the compound IX, for example: (1) Compound IX is oxidized by H 2 ⁇ 2 /carboxylic acid system, and the compound of the formula (I) is prepared by alkaline hydrolysis.
- the method comprises the following steps: (1 ⁇ ) adding compound IX and formic acid in a reaction flask, adding hydrogen peroxide dropwise at a low temperature, reacting for 1 to 2 hours, heating, adding water to stir and disperse, and filtering to obtain a white cake, drying.
- a white solid compound X is obtained, wherein compound IX: formic acid: hydrogen peroxide is: 1: 10 ⁇ 30: 0.5 ⁇ 3 (w: V: V);
- (1 b) an alkaline methanol solution is added to the reaction flask, and the compound is added in proportion.
- the reaction solution is poured into water to disperse, suction filtration, drying to obtain a white solid of the compound of formula (I), wherein the alkaline methanol solution is: potassium hydroxide, sodium hydroxide and sodium methoxide in methanol solution Any one of the above; the alkali concentration of the reaction liquid is: 2 to 10%.
- the alkaline methanol solution is: potassium hydroxide, sodium hydroxide and sodium methoxide in methanol solution Any one of the above; the alkali concentration of the reaction liquid is: 2 to 10%.
- the method comprises the following steps: (2 ⁇ ) adding compound IX and CH 2 CI 2 in a reaction flask, adding m-chloroperoxybenzoic acid in portions under stirring, stirring for 2 to 5 hours in an ice bath, and then ending the reaction. Washing with Na 2 C ⁇ 3 solution, Na 2 S solution and water, drying and concentrating to obtain compound XI; (2b) adding an acidic solution of compound XI and acetone in a reaction flask, stirring the reaction at room temperature for several hours, and ending the reaction After use
- Figure 2 shows that Compound I has a protective effect on glutamate-mediated cerebellar granule neuronal damage.
- Figure 3 shows that Compound I protects the survival of cerebellar granule neurons in a concentration-dependent manner.
- Figure 4 shows the protective effect of Compound I on hypokalemia-induced cerebellar granule neuronal death.
- Figure 5 shows a significant reduction in RGC in the optic nerve clipping injury model, while Compound I significantly prevented RGC reduction.
- Figure 6 shows the RGC statistics for each group of samples in the optic nerve clipping injury model.
- Figure ⁇ shows a significant reduction in RGC in the hyperbaric ischemia model, while Compound I reduces RGC loss from hypertensive ischemia.
- Figure 8 shows the RGC statistics for each group of samples in the high-pressure ischemia model.
- Li 2 C ⁇ 3 and 60.5 g of LiBr were heated under reflux, and it was confirmed by TLC that there was no compound VI, and the reaction was stopped. It was added to 2 L of a 1:1 (V:V) aqueous solution of glacial hydrochloric acid, stirred, suction filtered, and the filter cake was neutralized with water and dried to give 32 g of white solid compound IX.
- Steps (3) ⁇ (7) are the same as in Example 1 (3b (7).
- Steps m ⁇ (5) are the same as m ⁇ (5) in Example i.
- Steps (4) ⁇ (6) are the same as in Example 1 (5b (7).
- Steps m ⁇ (4) are the same as m ⁇ (4) in the example i.
- Steps m ⁇ (4) are the same as m ⁇ (4) in the example i.
- Steps (1) to (4) are the same as in Embodiment 1 (1 (4).
- Steps (1) to (5) are the same as in Embodiment 7 (1 (5).
- Step (7) is the same as Embodiment 7 (7).
- Steps (1) to (5) are the same as in Embodiment 7 (1 (5).
- Cell survival rate drug treatment group ⁇ D value / control ⁇ D value X I 00%. All data were expressed as mean ⁇ standard deviation, using the SPSS 1 3. 0 statistical software package, using one-Way ANOVA analysis of variance and ⁇ - ⁇ es ⁇ test, using Sigmaplo ⁇ software to obtain Figure 1. As can be seen from Figure 1, the survival rate of the drug-administered group was statistically significant compared with the control group after treatment with 250, 500, and 1 000 ⁇ of ⁇ C-1 0 for 24 h (P ⁇ 0.05). YC-l 0 is a dose-dependent killing tumor cell. Neuroprotective effect of compound I
- mice with high doses of YC-10 250 mg/kg had no abnormalities within 14 days after taking the drug; results of glutamate model and low potassium model of primary cerebellar granule neurons cultured in vitro It is shown that YC-1 0 has a significant protective effect on the survival of cerebellar granule neurons; animal model studies of optic nerve damage and retinal ischemia show that in the case of optic axonal injury and retinal ischemia, ⁇ C-1 0 It has a clear protective effect on the survival of optic ganglion cells. The above results indicate that YC-1 0 has no obvious side effects and has neuroprotective effects.
- mice were continuously observed, all mice were active, eating as usual, the hair color was bright, the fur was not loose, the mouth, the nose, the nose and the ear were free of abnormal secretions, and the urine was normal: the body weight increased, and none of the mice died.
- the animals were sacrificed, and the important organs such as heart, liver, spleen, lung, kidney, and gastrointestinal tract were examined by anatomy and meat restriction. No abnormal changes were observed. The results showed that 250 mg/kg of YC-1 0 was not toxic to mice.
- Rat cerebellar granule neurons were cultured on day 8 in vitro, and the drug-administered group was pre-incubated with MK801 or different concentrations of ⁇ C-1 0 for 30 min, and then the model group and all drug-administered groups were replaced with Locke buffer without Mg 2+ .
- the solution was administered with a final concentration of ⁇ ⁇ ⁇ glutamic acid, ⁇ ⁇ ⁇ glycine and the corresponding concentration of the drug, and placed in a 37 ° C incubator for 30 min, then returned to the normal medium, and continued to culture for 24 h before FDA staining.
- Rat cerebellar granule neurons were cultured on day 8 in vitro, and the drug-administered group was pre-administered with different concentrations of YC-10 for 30 min, and then the model group and the drug-administered group were replaced with 5K (ie, 5 mM KCI) BME medium (control group was 25K), the corresponding concentration of YC-1 0 was given at the same time, and the culture was continued in a 37 ° C incubator, and FDA staining was performed 24 hours later.
- 5K ie, 5 mM KCI
- microscopically observed low potassium media can induce cerebellar granule neuron death, while higher concentrations (50 ⁇ ) of YC-1 0 prevent hypokalemia-induced neuronal death.
- the results show that YC-1 0 has a protective effect on hypokalemia-induced cerebellar granule neuronal death.
- 2.3 YC-1 0 protects against optic ganglion cell death caused by optic nerve clipping injury
- Rats were anesthetized with 10% chloral hydrate. YC-1 0 (20 mg/kg) or solvent was given to the tail vein 20 min before surgery. Then local anesthesia was limited. The conjunctiva was cut along the limbus with corneal scissors and microscopic sputum. The external rectus muscle was separated, the optic nerve was fully exposed, and the optic nerve was clamped for about 2 mm after the restraining of the ball in the opposite direction for 5 seconds, and then the antibiotic was applied to prevent infection. The drug was administered again 2 hours, 2 days, and 3 days after surgery, and the ball was taken for pathological examination 7 days later.
- Rats were anesthetized with 10% chloral hydrate, local anesthesia was limited, and the perfusion device was placed so that the perfusion surface was 1 76 cm away from the limit level of the rat (approximately 1 30 mmHg internal pressure could be increased), and the nozzle was connected 30G 1 /2
- the needle carefully inserted into the anterior chamber, at this point, the limiting ball was clearly whitened and the ischemic onset time was recorded. After 1 hour, the needle was quickly pulled out, and the antibiotics were used to limit the medicine and then put back into the cage.
- the solvent group and the ⁇ C-1 0 group (20 mg/kg) were administered intravenously 20 minutes before the modeling, and the tail vein was administered again 2 hours, the next day and the third day after the modeling. After 7 days of modeling, the ball was taken for pathological examination.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2908088A CA2908088C (en) | 2013-03-28 | 2014-03-28 | 2.beta.,3.alpha.,5.alpha.-trihydroxy-androst-6-one and preparation methods and uses thereof |
KR1020157031029A KR101771192B1 (ko) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-트리하이드록시-안드로스트-6-원 및 이의 제조 방법 및 이의 용도 |
US14/780,464 US9428539B2 (en) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-trihydroxy-androst-6-one and preparation methods and use thereof |
SG11201507877QA SG11201507877QA (en) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-TRIHYDROXY-ANDROST-6-ONE AND PREPARATION METHODS AND USE THEREOF |
JP2016504473A JP6106328B2 (ja) | 2013-03-28 | 2014-03-28 | 2β,3α,5α−トリヒドロキシ−アンドロスタ−6−オン、その製造方法及びその用途 |
RU2015141335A RU2629929C2 (ru) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-ТРИГИДРОКСИ-АНДРОСТ-6-ОН, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
CN201480017073.XA CN105189528B (zh) | 2013-03-28 | 2014-03-28 | 2β,3α,5α‑三羟基‑雄甾‑6‑酮及其制备方法与用途 |
AU2014243510A AU2014243510B2 (en) | 2013-03-28 | 2014-03-28 | 2beta,3alpha,5alpha-trihydroxy-androst-6-one and preparation methods and use thereof |
EP14774834.7A EP2980096B1 (en) | 2013-03-28 | 2014-03-28 | 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof |
ES14774834.7T ES2691530T3 (es) | 2013-03-28 | 2014-03-28 | 2,3,5-trihidroxi-androst-6-ona y métodos de preparación y uso de la misma |
IL241768A IL241768B (en) | 2013-03-28 | 2015-09-21 | 2beta, 3alpha, 5alpha-trihydroxy-androstane-6-one, methods for its preparation and uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310104162.5A CN104072564B (zh) | 2013-03-28 | 2013-03-28 | 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 |
CN201310104162.5 | 2013-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014154179A1 true WO2014154179A1 (zh) | 2014-10-02 |
Family
ID=51594205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/074318 WO2014154179A1 (zh) | 2013-03-28 | 2014-03-28 | 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9428539B2 (zh) |
EP (1) | EP2980096B1 (zh) |
JP (1) | JP6106328B2 (zh) |
KR (1) | KR101771192B1 (zh) |
CN (2) | CN104072564B (zh) |
AU (1) | AU2014243510B2 (zh) |
CA (1) | CA2908088C (zh) |
ES (1) | ES2691530T3 (zh) |
IL (1) | IL241768B (zh) |
PT (1) | PT2980096T (zh) |
RU (1) | RU2629929C2 (zh) |
SG (1) | SG11201507877QA (zh) |
TW (1) | TWI504396B (zh) |
WO (1) | WO2014154179A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104561218B (zh) * | 2014-11-09 | 2019-01-11 | 浙江仙居君业药业有限公司 | 一种利用赤霉菌制备3β,7α,15α-三羟基雄甾-5-烯-17-酮的方法 |
CN109985048B (zh) * | 2017-12-29 | 2021-06-29 | 广州市赛普特医药科技股份有限公司 | 2β,3α,5α-三羟基雄甾-6-酮用于炎症反应的治疗 |
CN109985046B (zh) * | 2017-12-29 | 2021-07-27 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇用于炎症介导的视神经病变的治疗 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355809A (zh) * | 1999-03-23 | 2002-06-26 | 霍利斯-伊登医药公司 | 免疫调节性类固醇,特别是16α-溴表雄酮的半水合物 |
WO2011127465A2 (en) * | 2010-04-09 | 2011-10-13 | The Research Foundation Of The State University Of New York | Ship inhibitors and uses thereof |
CN102482315A (zh) * | 2009-07-29 | 2012-05-30 | 芝加哥大学 | 肝x受体激动剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
WO2006002907A1 (en) | 2004-06-29 | 2006-01-12 | Jadolabs Gmbh | Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
CN100355809C (zh) | 2004-12-27 | 2007-12-19 | 上海杰事杰新材料股份有限公司 | 一种应用于汽车、摩托车的尼龙燃油箱及其制备方法 |
CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
FR2967914A1 (fr) * | 2010-11-29 | 2012-06-01 | Centre Nat Rech Scient | Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques |
-
2013
- 2013-03-28 CN CN201310104162.5A patent/CN104072564B/zh active Active
-
2014
- 2014-03-28 CN CN201480017073.XA patent/CN105189528B/zh active Active
- 2014-03-28 KR KR1020157031029A patent/KR101771192B1/ko active IP Right Grant
- 2014-03-28 RU RU2015141335A patent/RU2629929C2/ru not_active IP Right Cessation
- 2014-03-28 EP EP14774834.7A patent/EP2980096B1/en active Active
- 2014-03-28 CA CA2908088A patent/CA2908088C/en not_active Expired - Fee Related
- 2014-03-28 AU AU2014243510A patent/AU2014243510B2/en not_active Ceased
- 2014-03-28 JP JP2016504473A patent/JP6106328B2/ja not_active Expired - Fee Related
- 2014-03-28 ES ES14774834.7T patent/ES2691530T3/es active Active
- 2014-03-28 TW TW103111715A patent/TWI504396B/zh not_active IP Right Cessation
- 2014-03-28 WO PCT/CN2014/074318 patent/WO2014154179A1/zh active Application Filing
- 2014-03-28 PT PT14774834T patent/PT2980096T/pt unknown
- 2014-03-28 SG SG11201507877QA patent/SG11201507877QA/en unknown
- 2014-03-28 US US14/780,464 patent/US9428539B2/en active Active
-
2015
- 2015-09-21 IL IL241768A patent/IL241768B/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355809A (zh) * | 1999-03-23 | 2002-06-26 | 霍利斯-伊登医药公司 | 免疫调节性类固醇,特别是16α-溴表雄酮的半水合物 |
CN102482315A (zh) * | 2009-07-29 | 2012-05-30 | 芝加哥大学 | 肝x受体激动剂 |
WO2011127465A2 (en) * | 2010-04-09 | 2011-10-13 | The Research Foundation Of The State University Of New York | Ship inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104072564A (zh) | 2014-10-01 |
PT2980096T (pt) | 2018-11-20 |
CA2908088A1 (en) | 2014-10-02 |
AU2014243510B2 (en) | 2016-08-04 |
US20160039862A1 (en) | 2016-02-11 |
CA2908088C (en) | 2017-02-07 |
CN105189528B (zh) | 2017-04-12 |
EP2980096A4 (en) | 2016-11-16 |
TW201436796A (zh) | 2014-10-01 |
US9428539B2 (en) | 2016-08-30 |
JP2016514729A (ja) | 2016-05-23 |
CN104072564B (zh) | 2016-08-17 |
EP2980096A1 (en) | 2016-02-03 |
KR101771192B1 (ko) | 2017-08-24 |
IL241768B (en) | 2019-07-31 |
ES2691530T3 (es) | 2018-11-27 |
EP2980096B1 (en) | 2018-08-15 |
CN105189528A (zh) | 2015-12-23 |
JP6106328B2 (ja) | 2017-03-29 |
KR20160021083A (ko) | 2016-02-24 |
RU2015141335A (ru) | 2017-05-16 |
SG11201507877QA (en) | 2015-10-29 |
TWI504396B (zh) | 2015-10-21 |
AU2014243510A1 (en) | 2015-10-15 |
RU2629929C2 (ru) | 2017-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109963844B (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
CN111132984A (zh) | 凋亡信号调节激酶1抑制剂的盐及其晶型 | |
EA032526B1 (ru) | Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы | |
CN106794174A (zh) | 治疗癌症的化合物 | |
WO2014154179A1 (zh) | 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途 | |
CN115515944A (zh) | 苯并噻唑类衍生物及其用途 | |
WO2012136133A1 (zh) | A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用 | |
WO2012175002A1 (zh) | 10-甲氧基喜树碱衍生物、制备方法和用途 | |
CN114948953A (zh) | 一种杂原子取代芳香类化合物及其盐的用途 | |
CN1990489A (zh) | 香豆草醚类化合物及其组合物的新用途 | |
US11396516B2 (en) | Tricyclic compounds as Cyp1 inhibitors | |
JP2001122871A (ja) | エストロゲン様作用薬剤 | |
CN107759553A (zh) | 新型类黄酮化合物及其用途 | |
CN114315930A (zh) | 化合物或其可药用盐、药物组合物及用途 | |
CN106188094B (zh) | 异噁唑环类衍生物及其制备方法和应用 | |
CN110227164A (zh) | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 | |
WO2017080313A1 (en) | Tetrahydropalmatine derivative, its preparation method and use | |
CN109988199B (zh) | 红景天苷衍生物及其用途 | |
CN1260245C (zh) | 薯蓣皂甙元丁二酸单酯衍生物及其制备方法和应用 | |
US20180215703A1 (en) | Stearoyl amino acid salt and method of use thereof | |
CN117427176A (zh) | 一种药物偶联物及其应用 | |
CN115558012A (zh) | 一种薯蓣皂苷元-丹参素衍生物及其自组装纳米颗粒和制备方法及用途 | |
EP4074707A1 (en) | Compound having neuroprotective effect, preparation method therefor and use thereof | |
DE112020006237T5 (de) | Deuterierte Analoga von Selenophenochromenen, deren Synthese und Verfahren zur Verwendung dieser Mittel | |
JP2024519933A (ja) | ヒアルロン酸複合体を含む皮膚疾患の予防または治療用薬学組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480017073.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14774834 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241768 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2908088 Country of ref document: CA Ref document number: 2016504473 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14780464 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014243510 Country of ref document: AU Date of ref document: 20140328 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014774834 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015141335 Country of ref document: RU Kind code of ref document: A Ref document number: 20157031029 Country of ref document: KR Kind code of ref document: A |